The scientific rationale behind the programme rests on a conceptual shift in how type 1 diabetes is understood. Earlier work by members of the consortium, including Dr Peter Achenbach and Professor Anette-Gabriele Ziegler of the Institute of Diabetes Research at Helmholtz Munich, established that the disease progresses through distinct presymptomatic stages before clinical onset. What was traditionally recognised as symptomatic diabetes is now classified as stage 3, while stages 1 and 2 describe earlier phases in which the immune system has already begun attacking the insulin-producing beta cells of the pancreas but blood glucose remains normal or only subtly abnormal. Identifying children during these presymptomatic windows matters because preventive and disease-modifying therapies are now becoming available. One such therapy, teplizumab, has already been approved to delay progression, and others are in development. Early detection also carries an immediate clinical benefit: children whose condition is known before symptoms appear face a substantially reduced risk of presenting with diabetic ketoacidosis, a life-threatening metabolic emergency that often marks the first diagnosis of type 1 diabetes.

The EDENT1FI consortium was designed to advance population-based screening and to harmonise early detection approaches across national borders. Using a common protocol, participating centres set out to assess the feasibility of screening for islet autoantibodies, to measure participation rates, to determine the prevalence of early-stage type 1 diabetes in the general child population, and to evaluate the performance and comparability of laboratory assays across different countries. Screening sites operated in the Czech Republic in Prague; in Denmark and Sweden in the Copenhagen and Öresund Region; in Germany in Munich, Hanover and Dresden; in Italy in Milan; in Poland in Warsaw and Katowice; in Portugal in Lisbon, Matosinhos and Beja; and in the United Kingdom in Birmingham.

The technical workflow followed a tiered design intended to balance sensitivity with practicality. Initial testing relied on capillary blood samples, collected as dried blood spots in the United Kingdom, and used a combined assay for three autoantibodies: GADA, directed against glutamic acid decarboxylase; IA-2A, directed against insulinoma-associated antigen-2; and ZnT8A, directed against zinc transporter 8. Samples that tested positive were then analysed for four autoantibodies, adding IAA, insulin autoantibodies, at two central laboratories in Munich and Milan. Participants with at least two confirmed autoantibodies underwent further confirmatory testing, and a diagnosis of early-stage type 1 diabetes was made only after this confirmation. Individuals diagnosed with early-stage disease were invited to receive education about their condition and to undergo metabolic staging through oral glucose tolerance testing and measurement of HbA1c, which distinguishes stage 1 disease, where glucose metabolism remains normal, from stage 2, where dysglycaemia has emerged, and from stage 3, where clinical symptoms develop.

Crucially, the screening targeted children from the general population, not only those with a known family history of the disease. Children and adolescents aged 2 to 10 years were eligible in Germany, while other countries screened those aged 2 to 17 years owing to site-specific variations in screening protocols. This general-population emphasis is scientifically important because the vast majority of children who develop type 1 diabetes have no first-degree relative with the condition, meaning that family-history-based risk stratification alone would miss most future cases.

In total, 140,568 young people, 49.2 percent of them female, took part in screening, with a median age of 7.6 years. Of these, 10,273 children, or 7.3 percent, had a first-degree family history of type 1 diabetes, while 127,754, or 90.9 percent, had no such relative, and family history was not reported for 2,541 participants. Among children with a first-degree relative with the disease, 219 were found to have early-stage type 1 diabetes, equivalent to 2.13 percent or roughly one in 45. Among children without a family history, 408 cases were detected, or 0.32 percent, approximately one in 350. These figures confirm that although genetic risk is elevated in relatives, the sheer size of the general population means that most presymptomatic cases are found among children with no family connection to the disease.

Country-level results revealed meaningful variation in prevalence. Among children without a first-degree relative with type 1 diabetes, frequencies ranged from 0.22 percent in Germany to 0.42 percent in the United Kingdom and 0.47 percent in Sweden. Prevalence was also associated with age: it was lowest, at 0.22 percent, among children younger than 4 years, rising to 0.31 percent in the 4 to under 8 age group and 0.40 percent among those aged 8 to under 13. In Italy, where screening took place in the EASD host city of Milan, 4,507 participants with a median age of 6.5 years were screened, including 3,641, or 80.8 percent, without a first-degree family history, of whom five, or 0.14 percent, had early-stage type 1 diabetes. No cases were detected among the 167 Italian children who did have a first-degree relative with the condition.

The larger national cohorts provided further detail. In the United Kingdom, 17,409 children with a median age of 8.4 years were screened; 59 cases, or 0.42 percent, were found among those without a first-degree relative with type 1 diabetes, and 67 cases, or 3.43 percent, among those with one. In Sweden, 7,926 children with a median age of 9.4 years were screened, yielding 36 cases, or 0.47 percent, among those without a family history and 4 cases, or 1.21 percent, among those with one. In Germany, where 43,470 children with a median age of 4.3 years were screened, case rates were notably lower, at 90 cases, or 0.22 percent, in children without a first-degree relative and 35 cases, or 1.36 percent, in those with one. The lower German figures may partly reflect the younger age distribution of the German cohort, given the observed rise in prevalence with age.

Of the 634 participants diagnosed with early-stage type 1 diabetes across the consortium, 386, or 61 percent, completed metabolic staging. The results showed that 300, or 78 percent, had stage 1 disease, 70, or 18 percent, had stage 2, and 16, or 4.1 percent, had already reached stage 3. This distribution underscores the value of antibody screening: the overwhelming majority of detected cases were identified at the earliest presymptomatic stage, when intervention opportunities are greatest. All participants identified with early-stage type 1 diabetes have been included in the European pre-T1D Registry, creating a harmonised continental cohort that can support future studies of disease progression and prevention.

The authors conclude that screening principles originally developed in Germany can be successfully applied to regions with different healthcare systems, and that the EDENT1FI initiative demonstrates that screening for early-stage type 1 diabetes can be effectively implemented throughout Europe. The next steps, they say, are aimed at integrating screening for early-stage type 1 diabetes in the general population into standard medical care. Similar screening initiatives are under way worldwide, including in the United States and Australia. Policy momentum is already visible within Europe: Italy has introduced legislation to establish nationwide screening for type 1 diabetes, although the government and regional health systems are still working to implement the law. The consortium recommends that screening be rolled out across Europe with three testing windows, at ages 2 to 4 years, 6 to 8 years and 10 to 15 years, an approach designed to capture the rising prevalence observed across childhood age groups while embedding early detection into routine paediatric care.

Subject of Research: Population-based screening of children for presymptomatic type 1 diabetes using islet autoantibody testing across eight European countries

Article Title: Study across eight European countries shows that screening for type 1 diabetes can be effectively implemented in children across Europe (EDENT1FI)

Article References: Study across eight European countries shows that screening for type 1 diabetes can be effectively implemented in children across Europe (EDENT1FI). (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: type 1 diabetes, EDENT1FI, islet autoantibodies, screening, EASD, presymptomatic stage, teplizumab, pediatrics, Europe, autoimmunity, diabetic ketoacidosis, public health

Type 1 diabetes is an autoimmune disease in which the insulin-producing beta cells of the pancreas are destroyed, meaning patients must rely on externally administered insulin for life. Because carbohydrate is the macronutrient with the most direct influence on blood glucose, the amount of carbohydrate a patient consumes has always been a central variable in insulin dosing. Conventional dietary guidance has generally encouraged moderate or higher carbohydrate intake combined with carefully matched insulin, partly out of concern that severe carbohydrate restriction could provoke dangerous metabolic disturbances in growing children. Yet in recent years a growing number of parents have begun experimenting with low and very low carbohydrate feeding strategies, often reporting striking improvements in their children’s glucose readings and a marked reduction in the amount of insulin needed each day.

Professor Christian Denzer, of the Department of Paediatrics and Adolescent Medicine, Division of Paediatric Endocrinology and Diabetes, at University Medical Center Ulm in Germany, who led the research together with Dr Belinda Lennerz of Boston Children’s Hospital and Harvard Medical School, explained the motivation behind the study. These diets are becoming more popular among people with diabetes, he noted, because patients themselves notice encouraging results, including much better blood sugar control and lower insulin needs. At the same time, he acknowledged that theoretical safety concerns have persisted, including the possibility of nutrient deficiencies, elevated cholesterol, low blood sugar episodes and ketoacidosis, a life-threatening complication of diabetes. In children, there is the additional worry that any restrictive diet could interfere with growth during critical developmental windows.

Until now, the evidence base for such diets in paediatric type 1 diabetes has been thin. Several observational studies and small interventional trials have corroborated the remarkable benefits on blood sugar and insulin requirements that patients report anecdotally, and no major safety events have been published to date. An earlier observational study led by Dr Lennerz, involving 316 children and adults, found major glycaemic benefits with mixed effects on cholesterol and no apparent adverse effect on growth or acute diabetes complications. But those studies were too small and too short to settle the question. What was needed, the researchers argued, was a large, long-term analysis capable of detecting rare complications and subtle effects on growth across a broad paediatric population.

To address this gap, the team turned to a diabetes prospective follow-up registry containing 25 years of longitudinal data collected from paediatric diabetes centres across Germany. From this resource they identified 45,569 children with type 1 diabetes, 55 percent of them male, with an average age of 10.3 years, whose carbohydrate intake had been recorded at least twice over a period of a year or more. This scale makes the analysis the largest of its kind ever performed, dwarfing previous investigations by orders of magnitude and providing the statistical power needed to examine both common outcomes and rare adverse events.

The children were grouped according to the carbohydrate percentage of their estimated energy intake. A very low carbohydrate group, comprising 219 children, consumed less than 10 percent of their energy from carbohydrate. A low carbohydrate group of 4,837 children obtained between 10 and less than 26 percent. The remaining 40,513 children followed a standard or higher carbohydrate diet of at least 26 percent. Average follow-up periods were 2.18 years for the very low carbohydrate group, 2.40 years for the low carbohydrate group and 3.67 years for the standard carbohydrate group. The researchers tracked height and weight, adjusting for the fact that the children were still growing, alongside changes in glycaemic trajectories, insulin use and the rates of the two most feared severe metabolic complications of diabetes: hypoglycaemia and diabetic ketoacidosis.

The analysis did not flag up any safety concerns in the areas examined. There was no evidence that a very low carbohydrate diet stunted growth, and no association between very low carbohydrate intake and either severe hypoglycaemia or diabetic ketoacidosis. This absence of harm signals is significant because both complications represent the principal acute dangers of type 1 diabetes. Severe hypoglycaemia, in which blood glucose falls to dangerously low levels, can cause seizures, loss of consciousness and, in extreme cases, death. Diabetic ketoacidosis arises when the body, starved of insulin, begins breaking down fat at an uncontrolled rate, producing acidic ketone bodies that overwhelm the blood’s buffering capacity and can rapidly become fatal without emergency treatment. Critics of carbohydrate restriction have long argued that pushing children into a state of relative ketosis might tip vulnerable patients toward ketoacidosis, but the registry data found no support for that fear.

On the benefit side, lower carbohydrate intake was associated with several favourable changes. Body mass index increased less over time in children following very low and low carbohydrate diets than in those on standard diets, meaning their weight remained closer to a healthier range as they grew. Levels of HbA1c, the laboratory measure that reflects average blood sugar over the preceding two to three months, were lower at the end of follow-up and rose less steeply over time in the lower carbohydrate groups. Doses of basal insulin, one of the two types of insulin typically prescribed for type 1 diabetes, followed the same pattern, being lower at the end of the observation period and increasing less over time among children eating less carbohydrate.

Most notably, the study examined a composite metric known as IDAA1c, which combines blood sugar levels with the amount of insulin a person requires. Dr Lennerz explained the significance of this measure: a lower IDAA1c means that better blood sugar control was achieved without simply using more insulin, strengthening the finding that very low and low carbohydrate diets were associated with both better glycaemic control and lower insulin requirements. This distinction matters because a patient could in principle achieve normal glucose readings by escalating insulin doses, but doing so increases the risk of hypoglycaemia and weight gain. A dietary approach that improves glucose control while simultaneously reducing insulin need therefore represents a genuinely favourable metabolic profile rather than a trade-off between competing risks.

The analyses were adjusted for factors including sex, age, migration background and diabetes duration, but the authors caution that the observational design leaves room for residual confounding. Families who choose very low carbohydrate diets may differ from other families in ways the registry cannot fully capture, including health consciousness, socioeconomic resources and the accuracy of self-reported dietary intake. Dr Lennerz concluded that reducing carbohydrate intake improved glycaemic control while reducing insulin needs without negatively impacting growth or increasing the rate of acute diabetes complications, describing the results as very encouraging but emphasising that they remain observational in nature. Additional research, she said, is needed to confirm the findings and establish the ideal amount of carbohydrate intake to maximise benefits while avoiding adverse effects and promoting food variety. For now, the study offers the strongest evidence yet that carbohydrate restriction in children with type 1 diabetes is not the hazard many clinicians feared, while leaving open the question of where the optimal balance lies.

Subject of Research: Effects of very low carbohydrate diets on growth and metabolic safety in children with type 1 diabetes

Article Title: Very low carbohydrate diets linked to health benefits in children with type 1 diabetes, largest study of its kind finds

Article References: Very low carbohydrate diets linked to health benefits in children with type 1 diabetes, largest study of its kind finds. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: type 1 diabetes, very low carbohydrate diet, paediatrics, HbA1c, IDAA1c, insulin requirement, hypoglycaemia, diabetic ketoacidosis, growth, registry study, EASD, nutrition

The study was led by PhD student Maria Östman of the University of Oslo and colleagues, who exploited one of the fastest and most complete vaccine introductions in Europe as a natural experiment. When Norway added the monovalent Rotarix vaccine to its national childhood immunisation programme in September 2014, uptake among infants reached 92.8 percent within a short period. That near-total and abrupt shift created a clean dividing line in the population: children born before the introduction had essentially no rotavirus vaccination in infancy, while those born after it were overwhelmingly vaccinated. Such a sharp exposure boundary is rare in epidemiology, and it allowed the researchers to compare diabetes incidence across birth cohorts with unusual clarity.

Rotavirus is a highly common virus transmitted by the faecal–oral route and a leading cause of severe gastroenteritis in young children, particularly those under five years of age. Immunity builds with each infection, so repeat infections tend to be milder, but first infections can be dangerous. Rotavirus vaccines, which are oral live-attenuated products made from a laboratory-weakened virus, have dramatically reduced hospitalisation and mortality from severe rotavirus disease worldwide. Because viral infections have long been suspected of influencing the risk of type 1 diabetes — an autoimmune disease in which the immune system destroys the insulin-producing beta cells of the pancreas — researchers have debated whether rotavirus vaccination might either raise or lower diabetes risk. Previous studies in other countries have produced conflicting results, with some suggesting a protective effect and others finding no association.

To resolve the question in the Norwegian setting, the researchers followed all children born in Norway between 2007 and 2019, a total of 740,744 children, from the age of six months to five years. Crucially, they ensured that the length of follow-up was identical for children born before and after the vaccine’s introduction, eliminating a common source of bias in cohort comparisons. Data collection continued until 31 December 2024. Among the full cohort, 846 children were diagnosed with type 1 diabetes before their fifth birthday. The researchers then applied an interrupted time series analysis, a statistical technique that uses the observed pre-vaccination trend to predict what incidence would have been without the intervention, and compares that prediction with the actual observed trend afterwards.

The main analysis showed a relative increase of 11 percent in type 1 diabetes incidence among children born after the vaccine’s introduction compared with the predicted trend. In a separate adjusted analysis, the relative hazard ratio for children fully vaccinated with two doses of the monovalent vaccine, compared with unvaccinated children, was 1.17 — an apparent elevation that, however, did not reach statistical significance. The authors summarised their central finding bluntly: the study found no evidence for a reduced risk of type 1 diabetes after the introduction of rotavirus vaccination in infancy, but instead found that incidence before age five increased after vaccination was introduced. Taken at face value, that combination of results could have fuelled concerns about the vaccine’s safety.

It is here that the study’s secondary analyses become decisive. To test whether the observed increase was genuinely attributable to the rotavirus vaccine, the researchers examined what happened to diabetes incidence after other, unrelated changes to the Norwegian immunisation programme. These served as negative controls: there is no biological or epidemiological evidence that the introduction of the hepatitis B vaccine in 2016, or the switch from the 7-valent to the 13-valent pneumococcal vaccine in 2011, would affect type 1 diabetes risk. If the association seen after the rotavirus rollout reflected a true vaccine effect, similar associations should not appear around these unrelated programme changes. Yet they did. The incidence of type 1 diabetes among children born after the hepatitis B vaccine’s introduction rose by a magnitude similar to that seen after the rotavirus rollout, and the same pattern followed the pneumococcal vaccine switch.

The authors interpret this convergence as strong evidence that the initial 11 percent finding is probably not related to the rotavirus vaccine at all, but rather to other, as yet unknown changes in the environment affecting Norwegian children. Type 1 diabetes incidence has generally been increasing over recent decades, with year-to-year fluctuation, and the researchers emphasise that they do not believe any of the changes in the national vaccination programme, individually or in combination, explain the rise. As they put it, despite their best efforts to design the study to remove the influence of other unknown factors, the identical pattern appearing around every programme change — including changes hypothesised to have opposite or null effects — points to unidentified environmental factors operating across the period.

The team also systematically considered alternative explanations for the observed increase. The COVID-19 pandemic, which was followed in many countries by a temporary surge in paediatric type 1 diabetes diagnoses, was one candidate; Norway itself experienced a temporary increase in incidence in 2022 followed by a decrease. However, a recent study of Swedish and Norwegian adolescents found no increase in type 1 diabetes incidence after COVID-19 infection, weakening that hypothesis. The researchers also examined a change in Norwegian prenatal care guidelines in June 2018, which began recommending measurement of serum ferritin concentration in the first trimester of pregnancy to determine the need for iron supplementation, replacing the less sensitive measurement of haemoglobin at week 30. Because high iron levels have been suspected of association with type 1 diabetes, the change warranted scrutiny. The authors concluded it was unlikely to be relevant, noting that iron levels are usually low in pregnancy and that only children born in 2019 within the study window were affected by the new recommendations.

The authors are careful about the limits of their conclusions. They state that they do not believe rotavirus vaccination increases the risk of type 1 diabetes, but they also argue that additional studies of rotavirus vaccination and type 1 diabetes are needed in different settings and with different vaccines before any definitive conclusion is drawn. This matters because vaccine formulations differ across countries: Norway and the United Kingdom use the monovalent Rotarix vaccine alone, Germany and Italy use both Rotarix and the pentavalent RotaTeq vaccine, while Finland and Iceland implemented RotaTeq alone. Replication across these different exposure profiles would help determine whether the Norwegian findings hold elsewhere or are artefacts of local circumstances. The authors also stress the broader need for research into other environmental factors that could be associated with type 1 diabetes, given that the disease’s incidence continues to climb in many populations without a fully established cause.

For the public, the practical message is one of reassurance grounded in methodological rigour. Rotavirus vaccination has efficiently reduced hospitalisation and mortality from severe rotavirus infections in children, and the Norwegian data, once subjected to negative-control scrutiny, do not support the idea that the vaccine drives diabetes risk in early childhood. The study instead illustrates a subtle pitfall of interrupted time series designs: when a long-running upward trend in a disease coincides with a policy change, the change can appear causal even when it is not. By testing the same pattern against interventions with no plausible link to diabetes, the Oslo team showed that the 11 percent rise was more plausibly a marker of some other environmental shift affecting children born from September 2014 onward. The authors declare no conflict of interest, and their work stands as a model of how vaccine safety signals should be interrogated — thoroughly, transparently, and with controls designed to catch spurious associations before they harden into public fear.

Subject of Research: Association between rotavirus vaccination and type 1 diabetes incidence in Norwegian children

Article Title: Nationwide study in Norway shows a relative 11% increase in incidence of type 1 diabetes in children aged 0.5 to 5 years after nationwide introduction of rotavirus vaccine, but secondary analyses suggest vaccine probably not the cause

Article References: Nationwide study in Norway shows a relative 11% increase in incidence of type 1 diabetes in children aged 0.5 to 5 years after nationwide introduction of rotavirus vaccine, but secondary analyses suggest vaccine probably not the cause. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: type 1 diabetes, rotavirus vaccine, Rotarix, Norway, EASD, Diabetologia, interrupted time series, childhood immunisation, epidemiology, negative controls, autoimmune disease, vaccine safety

The question the researchers set out to answer is deceptively simple but has long eluded epidemiologists. It is well established that people living in poorer areas face a higher risk of type 2 diabetes, but correlation is not causation. People who live in deprived neighbourhoods may differ from those in wealthier ones in income, education, occupation, diet and countless other ways, making it difficult to disentangle the effect of the place itself from the characteristics of the people who live there. The sharper question is whether changing neighbourhoods matters at all: does a person’s likelihood of developing type 2 diabetes actually fall if they move from a high-poverty area to one that is less deprived?

To address this, Sharmin Majumder of the Institute of Health Policy, Management and Evaluation at the University of Toronto, together with colleagues at a range of other institutions in Toronto, examined health records covering almost two million adults in Ontario, Canada. The dataset included 1,932,869 men and women with an average age of 42.1 years, roughly 51 percent of whom were female. All participants were free of diabetes at the start of the observation period and were living in high-poverty areas, defined as neighbourhoods where at least 30 percent of households fall below Statistics Canada’s after-tax Low-Income Cut-Off, a standard poverty threshold. The researchers then followed these individuals for up to 21 years, tracking who developed type 2 diabetes and how their residential circumstances changed over time.

The analytical design divided the population into comparison groups. Individuals who moved from a high-poverty neighbourhood to a lower-poverty one were compared with those who relocated to another high-poverty neighbourhood, and with those whose residential status did not change at all. Because people who move are almost certainly different from people who stay, in health, motivation, resources and life circumstances, the team applied a statistical technique known as inverse probability weighting. This method reweights the comparison groups so that they become more similar on measured characteristics such as age, sex, immigration background, neighbourhood walkability and city size, reducing the distortion that would otherwise arise from these systematic differences between movers and stayers.

The results were striking. Adults who moved from a high-poverty neighbourhood to a lower-poverty one developed type 2 diabetes at a rate 24 percent lower during follow-up than those who moved to another high-poverty neighbourhood. Even more dramatically, their rate of new diabetes diagnoses was 57 percent lower than that of people who remained in the same high-poverty area throughout the study period. Taken together, the findings indicate that the destination of a move matters enormously: relocating within deprivation was associated with some benefit relative to staying put, but the clearest and largest reduction in risk was seen among those who crossed the poverty threshold into less disadvantaged surroundings.

One secondary observation in the data deserves careful handling. The analysis suggested that people who remained in the same high-poverty neighbourhood were more likely to develop diabetes than those who moved from one high-poverty neighbourhood to another. The study, however, was not designed to explain this difference, and the researchers themselves urge restraint in interpreting it. As Dr Majumder noted, people who move may differ from people who do not move in ways that are difficult to fully measure, so this particular finding should be read cautiously and requires further investigation before any firm conclusions are drawn about why stayers fared worse than even within-poverty movers.

What might explain the protective effect of moving to a wealthier area? The authors point to a constellation of neighbourhood-level features that plausibly shape metabolic health. Lower-poverty neighbourhoods may differ from high-poverty ones in the presence of healthy and affordable food retailers, giving residents easier access to fresh produce and balanced diets. They may offer more opportunities for physical activity, including greater neighbourhood walkability and more green spaces. Investments in healthcare and other community resources also tend to be more abundant, potentially improving both the prevention and the management of conditions that precede diabetes. None of these mechanisms was directly tested in the study, and identifying which pathways carry the greatest weight is, according to the researchers, an important next step.

Environmental conditions add another layer to the picture. Dr Majumder highlighted that neighbourhoods can differ with respect to factors that affect stress and health, such as traffic-related air pollution and noise, as well as the opportunities residents have to make social connections. Chronic stress, air pollution and social isolation have each been linked in prior research to disturbances in glucose metabolism and inflammation, offering biologically plausible routes by which the built and social environment could influence diabetes risk. The new findings do not prove these mechanisms, but they are consistent with a growing body of evidence that health is produced not only inside bodies and clinics but in the streets, parks and shops that surround people every day.

The implications extend well beyond academic curiosity. Dr Majumder argues that learning more about which neighbourhood conditions are linked to better health is important for urban planning and, by extension, for public health. The findings suggest that where people live has important implications for their long-term health, and understanding which specific conditions are protective could help inform urban revitalisation efforts and initiatives to improve disadvantaged communities. Concrete examples she cites include better housing, more walkable environments, safe recreational spaces and improved access to community resources. In other words, if place shapes diabetes risk, then changing place, whether by helping families move or by transforming the neighbourhoods they already inhabit, could become a legitimate instrument of chronic disease prevention.

Several caveats frame the work. The study is observational, so even the careful statistical weighting cannot rule out the influence of unmeasured differences between movers and non-movers, and the presentation at a scientific conference means the findings have not yet completed full peer review in a journal. The authors declare no conflicts of interest. Nevertheless, the sheer scale of the dataset, nearly two million adults followed for up to two decades, and the consistency of the association lend considerable weight to the central conclusion: moving from a high-poverty neighbourhood to a lower-poverty one was associated with a substantially lower risk of developing type 2 diabetes. For a disease that affects hundreds of millions of people worldwide and is driven largely by modifiable environmental and behavioural factors, the message that the address on an envelope may be part of the prescription is a provocative one, and it is likely to fuel debate among policymakers, urban planners and health researchers for years to come.

Subject of Research: The association between neighbourhood poverty, residential mobility and type 2 diabetes risk

Article Title: How moving neighbourhood can alter risk of type 2 diabetes

Article References: How moving neighbourhood can alter risk of type 2 diabetes. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: type 2 diabetes, neighbourhood poverty, residential mobility, epidemiology, public health, urban planning, Ontario, EASD, inverse probability weighting, social determinants of health, walkability, University of Toronto

Early onset type 2 diabetes, abbreviated EOT2D, is increasingly recognised by clinicians as a distinct and particularly aggressive clinical phenotype. Because it strikes in the third and fourth decades of life, the disease has decades longer to inflict damage on blood vessels, nerves, kidneys and the heart. People diagnosed young experience more rapid deterioration in blood sugar control, develop complications earlier, and face a lower life expectancy than those whose type 2 diabetes appears later in life. As rates of obesity rise across the globe, the number of young adults affected is climbing steeply, making the search for potent, disease-modifying interventions an urgent priority for health systems worldwide.

The biological rationale behind the trial, known as RESET for Remission, rests on the complementary effects of dietary energy restriction and exercise. Low energy diets have previously been shown to drive glucose levels below the diagnostic threshold for type 2 diabetes without the need for medication, a state defined as remission. Adding structured exercise may deliver synergistic advantages: greater cardiorespiratory fitness, preservation of muscle mass during rapid weight loss, enhanced cardiac function, and reduced insulin resistance. The researchers reasoned that a condition as aggressive as early onset type 2 diabetes merits an intervention powerful enough to arrest its swift evolution, and they designed the study to test whether combining the two approaches would outperform usual care.

The trial was a randomised, open-label, blinded endpoint efficacy study conducted across three centres in England and Canada, affiliated with the University of Leicester, McGill University in Montreal, and the University of Alberta in Edmonton. It enrolled adults aged 18 to 45 with early onset type 2 diabetes and obesity who were not taking insulin therapy. Between September 24, 2021 and June 6, 2025, a total of 96 participants were randomised, 40 in the United Kingdom and 56 in Canada. The intervention group comprised 24 women and 26 men, while the control group had 21 women and 25 men. The mean age of participants was 38 years and the mean body mass index was 35.2 kilograms per square metre. Notably, 86 participants, or 90 percent, attended final assessments, a retention rate that strengthens confidence in the findings.

The intervention itself was demanding but carefully structured. Participants stopped all glucose-lowering and blood pressure-lowering medication, in the absence of albuminuria, as they began an 800 to 900 kilocalorie per day diet providing 30 percent of energy from protein, 50 percent from carbohydrate and 20 percent from fat. They were encouraged to drink at least two litres of calorie-free fluid daily and were given a fibre-based laxative to use as required. The first two weeks consisted of total meal replacement using Optifast. From weeks 3 to 12, the same caloric intake continued with more variety, using Optifast in the United Kingdom and ProtiDiet in Canada, alongside one food-based meal per day supplying 60 to 90 grams of protein from all sources combined, one portion of fruit and two portions of non-starchy vegetables.

Exercise ran in parallel with the dietary phase. During weeks 1 to 12, participants completed twice-weekly supervised sessions covering both aerobic and resistance training, plus one weekly independent exercise session. From weeks 13 to 24, they transitioned to a weight-maintenance diet while continuing independent exercise. The primary outcome was remission at 24 weeks, defined as a glycated haemoglobin level below 6.5 percent, or 48 millimoles per mole, together with the absence of glucose-lowering medication for at least 12 weeks. The primary efficacy and harms analysis included all randomised individuals, with a conservative assumption that missing data meant no remission. Secondary endpoints captured cardiorespiratory fitness, body composition and cardiac structure.

The results were striking across multiple dimensions. Intervention participants, who averaged 100.7 kilograms at baseline, lost a mean of 8.4 kilograms by week 24, reaching an average weight of 92.3 kilograms. Control participants, who averaged 103.2 kilograms at the start, lost only 1.2 kilograms, ending at a mean of 102.0 kilograms. After statistical adjustment, the analysis showed that intervention participants lost 7.5 kilograms more than controls, including 6.6 additional kilograms of fat mass. Critically, the trial demonstrated that fat-free mass and muscle preservation are achievable even during rapid weight loss, a finding the authors attribute to the resistance training component that deliberately targeted muscle during the intensive dietary phase.

Safety data were reassuring. Remission was achieved without any severe adverse events. Most participants in the intervention group, 43 of 50, experienced at least one adverse event, compared with 6 of 46 in the control group, but these were mainly the familiar early effects of very low energy diets, such as constipation, headache, dizziness and fatigue, all of which resolved. This profile mirrors what has been reported in previous meal replacement trials and suggests that, under appropriate supervision, the intervention is tolerable for the majority of young adults willing to undertake it.

The authors emphasised the breadth of the benefits beyond blood sugar control. In their summary of the RESET for Remission findings, they report that combining structured aerobic and resistance exercise with a low-calorie diet produced high remission rates, induced fat loss while preserving muscle mass, improved muscle quality and function, enhanced cardiovascular health, and led to meaningful improvements in patient-reported outcomes. They noted that their remission rates sit at the upper end of those previously reported in the literature for trials of similar duration, and that this is the first time such effects have been demonstrated in a multi-ethnic population with early onset type 2 diabetes through a combined low energy diet and structured exercise intervention.

The researchers are candid about the challenges that remain. All weight loss programmes, including low energy diets used for type 2 diabetes remission, are typically followed by a period of partial or full weight regain for most people. Because weight loss driven by lower energy intake alone reduces both fat and fat-free mass, and there is some evidence that weight regain may preferentially restore fat over fat-free mass, there is a long-term risk of net muscle loss and increased sarcopenia. Preserving muscle during remission-oriented weight loss, they argue, may have important implications for long-term metabolic health, physical function and disease trajectory, though this requires confirmation in longer-term studies. They also highlight that their approach may be particularly valuable for those seeking or with potential for pregnancy, a group in which medication options are limited. As the global prevalence of early onset type 2 diabetes continues to rise, the team concludes that the findings present an opportunity to re-evaluate treatment paradigms and support scalable implementation of integrated dietary and exercise interventions, pending further evaluation in real-world settings.

Subject of Research: Remission of early onset type 2 diabetes through a combined low energy diet and structured exercise intervention

Article Title: Study shows low energy diet combined with structured exercise reverses early onset type 2 diabetes in half of participants

Article References: Study shows low energy diet combined with structured exercise reverses early onset type 2 diabetes in half of participants. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: type 2 diabetes, diabetes remission, low energy diet, structured exercise, early onset diabetes, randomised controlled trial, weight loss, resistance training, McGill University, University of Leicester, EASD, The Lancet Regional Health Americas

The study is notable less for its size than for its novelty. Until now, all evidence on this topic came from questionnaires and interviews rather than measured physiology. In one frequently cited survey of 53 young adults with type 1 diabetes, roughly one third reported fearing hypoglycaemia during sexual activity. But no one had ever tracked what actually happens to blood glucose in the hours surrounding sex. The Warsaw team set out to close that gap by combining real-time CGM data with participant-reported events, creating the first objective physiological picture of glucose dynamics during and after sexual intercourse in people with type 1 diabetes.

Dr Orłowska explained the clinical reasoning behind the research. On paper, sex is physical exertion like any other, and exertion lowers glucose. In practice, however, it behaves differently from planned exercise. A person preparing for a workout can reduce an insulin dose, eat carbohydrates beforehand, or activate an exercise mode on an insulin pump. Sexual activity, by contrast, is usually spontaneous, and it typically occurs in the evening or at night — precisely the window in which severe and unnoticed hypoglycaemia is most likely. Compounding the problem, she noted, is silence: patients routinely discuss exercise with their diabetologists and receive concrete advice, but almost nobody asks about sex, so the fear is never addressed. Yet sexual life is central to quality of life, and fear of hypoglycaemia can lead people to avoid intimacy entirely.

To investigate, the researchers enrolled 12 adults with type 1 diabetes — seven women and five men — in a prospective observational study. Participants had a median age of 36 years, ranging from 21 to 64, and a mean body mass index of 24 kg/m². All wore CGM devices, either the FreeStyle Libre 2 or the Guardian 4. Six were treated with multiple daily insulin injections and six with insulin pump therapy, including two using automated insulin delivery systems. None of the five male participants reported erectile dysfunction. Over a three-month period, participants marked each instance of sexual intercourse in their CGM application, allowing the researchers to analyse glucose data from two hours before to six hours after every event.

In total, 110 sexual intercourse events were recorded. A telling behavioural detail emerged: all participants using insulin pump therapy reported removing their devices during sex, meaning glucose readings during the events themselves came from the surrounding CGM trace rather than pump-integrated data. Despite the potential for exertion-related glucose drops, no clinically significant hypoglycaemia was observed anywhere in the dataset. Blood sugar changes were also unrelated to insulin therapy mode or to how long a participant had lived with diabetes, suggesting the response pattern is broadly consistent across treatment approaches.

The most striking finding was the bidirectionality of the glucose response. In 64 events, representing 58 percent of the total, mean post-intercourse glucose fell by 27 percent, from 180 to 132 mg/dL — a statistically significant decrease. In the remaining 46 events, or 42 percent, glucose rose by 34 percent, from 122 to 164 mg/dL, also statistically significant. Both increasing and decreasing patterns were observed within every single participant, meaning no individual could be classified as a consistent

The direction of the glucose response was not random. Higher glucose levels before intercourse were associated with a greater subsequent fall when glucose declined, and with a smaller rise when glucose increased, suggesting the body’s response may partly depend on the starting metabolic state. This bidirectional pattern echoes what is known about exercise physiology more broadly: physical activity typically lowers glucose by increasing muscle glucose uptake, but factors such as adrenaline, anticipatory stress, and circulating insulin levels can push glucose in the opposite direction. Sexual activity combines elements of exertion with emotional arousal, and the new data suggest these competing forces can net out in either direction in any given encounter.

Timing emerged as a meaningful variable. Of the 110 recorded events, 66 occurred at night, defined as between 20:00 and 06:00, and these nighttime events were associated with a statistically significant reduction in glucose levels, from a mean of 165 to 147 mg/dL. Daytime events, numbering 44, produced essentially no change, with mean glucose moving only from 144 to 143 mg/dL. The researchers also found no difference between mean glucose measured two hours after intercourse and six hours after, indicating that any glucose effects of sexual activity had largely settled within the first two hours rather than producing delayed drops hours later. That detail matters clinically, since delayed-onset hypoglycaemia is a well-recognised hazard after vigorous exercise and a common source of anxiety among people using insulin.

Body composition appeared to influence the response as well. Participants with a body mass index of 25 or higher showed a statistically significant post-intercourse glucose decrease of 10.7 percent, from 150 to 134 mg/dL, while those with a BMI under 25 showed a smaller, non-significant decline of 5.6 percent, from 159 to 150 mg/dL. The authors suggest this may reflect differences in energy expenditure, insulin sensitivity, or muscle mass, though the small sample size makes it impossible to draw firm conclusions. Diabetes duration, meanwhile, had no detectable effect on glucose responses, and neither did the mode of insulin delivery, whether multiple daily injections, conventional pump therapy, or automated insulin delivery.

The study’s limitations deserve emphasis. Twelve participants and 110 events are enough to generate hypotheses and provide reassurance, but not enough to establish definitive risk estimates for subgroups. All participants were adults in mid-life on average, with a normal mean BMI, and none of the men reported erectile dysfunction, so the findings may not extend to people with diabetes-related sexual dysfunction, older adults, or those with hypoglycaemia unawareness, a condition in which the normal warning symptoms of falling glucose are blunted. People with impaired awareness of hypoglycaemia are generally considered at higher risk during any unplanned activity, and clinicians may reasonably advise more cautious monitoring for them regardless of these results.

There is also the question of what the CGM trace can and cannot capture. Because every pump user removed their device during intercourse, the analysis relied on interstitial glucose readings from the surrounding period, and interstitial glucose lags behind blood glucose by several minutes to more than a quarter of an hour. Rapid changes during the event itself could therefore be somewhat smoothed or delayed in the recorded data. The researchers defined clinically significant hypoglycaemia according to standard thresholds used in diabetes research, and no readings crossed those thresholds, but the study was not powered to detect rare events. A single severe episode among hundreds of encounters would not necessarily appear in a dataset of this size.

Even with those caveats, the findings carry practical weight for clinical counselling. Diabetes care guidelines encourage clinicians to discuss the impact of physical activity on glucose, but sexual activity is rarely mentioned, and patients rarely raise it themselves. Dr Orłowska and her colleagues argue that the silence itself is harmful: fear of hypoglycaemia during sex can lead to avoidance of intimacy, strain on relationships, and reduced quality of life, all of which are recognised concerns in diabetes care yet seldom addressed in routine consultations. Objective evidence that intercourse does not typically provoke dangerous glucose lows gives clinicians a concrete, evidence-based starting point for those conversations.

The results also offer a framework for individualised advice rather than blanket reassurance. Because starting glucose level, time of day, and BMI all appeared to shape the glucose response, people with type 1 diabetes and their clinicians can use these factors when thinking about personal risk. Someone beginning sexual activity with a glucose level already trending low at night may reasonably choose to check a reading beforehand or keep fast-acting carbohydrates within reach, while someone starting from a higher glucose level may see little change or even a rise. The observation that glucose effects settled within two hours, with no delayed divergence at the six-hour mark, may further ease worries about overnight lows following evening intimacy.

The authors close with a reminder about technology access. In an ideal world, they note, every person with type 1 diabetes would use continuous glucose monitoring; those who do not may have no way of knowing whether they experience hypoglycaemia during sex or in any other setting. For the growing number of CGM users, however, the device itself offers a simple tool: marking events and reviewing the surrounding trace can turn an abstract fear into personal data. As the first study to measure glucose objectively in this context, the Warsaw work transforms a question that has lived only in surveys and unspoken anxieties into an answerable physiological one, and it opens the door to larger studies in more diverse populations.

Subject of Research: Glucose responses to sexual intercourse in adults with type 1 diabetes measured by continuous glucose monitoring

Article Title: Sex is safe in type 1 diabetes, shows small study using continuous glucose monitoring devices

Article References: Sex is safe in type 1 diabetes, shows small study using continuous glucose monitoring devices. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: type 1 diabetes, continuous glucose monitoring, hypoglycaemia, sexual intercourse, EASD, blood glucose, insulin therapy, quality of life, observational study, Medical University of Warsaw, nocturnal hypoglycaemia, diabetes counselling

Completing a marathon with type 1 diabetes is a metabolic balancing act of unusual complexity. Every kilometre of running consumes muscle glycogen and blood glucose, while carbohydrate intake, insulin sensitivity, adrenaline, dehydration and core temperature all push glucose levels in different directions at different times. Too much circulating insulin, or too little carbohydrate on board, risks hypoglycaemia, a dangerous drop in blood sugar that can cause confusion, collapse or worse. Too little insulin risks hyperglycaemia and ketoacidosis. Despite the well-documented health benefits of regular exercise, fear of these low-glucose episodes remains the single biggest barrier to physical activity for people with type 1 diabetes, affecting up to 45 per cent of those living with the condition.

To examine how amateur runners actually manage this challenge, the researchers designed an observational study built around the 2025 Poznań Marathon, a standard 42-kilometre road race. They recruited 20 amateur runners: 10 with type 1 diabetes of at least one year’s duration and 10 controls without diabetes. The two groups were well matched, showing no significant difference in age (a mean of 35.4 years in the diabetes group versus 39.7 years in the controls), and each group contained eight men and two women. Among the runners with type 1 diabetes, the median duration of the condition was 16.5 years and median glycated haemoglobin, a measure of long-term glucose control, stood at 6.4 per cent, indicating generally well-managed diabetes.

Before the race, each runner with type 1 diabetes followed an individualised insulin strategy agreed in advance. The target pre-race glucose range was set at 140 to 200 mg/dL, deliberately above the normal fasting range to create a safety buffer for the exercise-induced drops to come. Runners using multiple daily injections reduced their basal insulin dose by 25 per cent, while those using non-hybrid insulin pumps cut basal delivery by 50 per cent. Participants on hybrid closed-loop systems, which automatically adjust insulin delivery, instead set a target glucose of 150 mg/dL. Five runners used multiple daily injections, three used continuous subcutaneous insulin infusion pumps, and two used automated insulin delivery systems, reflecting the full spectrum of modern insulin therapy.

Glucose was assessed at five checkpoints along the course: the start line, 10 km, 19 km, 30 km and the finish. At each point, capillary glucose was measured with a standard fingerstick glucometer and compared against readings from two different CGM systems, one intermittently scanned and one transmitting in real time. Carbohydrates or insulin were administered as required throughout the race. The researchers also evaluated the accuracy of the CGM devices using mean absolute relative difference, or MARD, a standard metric that expresses the average absolute percentage difference between sensor readings and reference glucose values. The lower the MARD, the more faithfully the sensor tracks true blood glucose.

The headline performance result was striking in its ordinariness. Marathon completion times did not differ significantly between the groups, with a median finishing time of 228 minutes for the runners with type 1 diabetes and 248 minutes for the controls. In other words, with careful preparation, the runners with diabetes were not merely surviving the distance; they were racing it on equal terms. During the race, they consumed a median of 53.5 grams of carbohydrate per hour, equivalent to 2.61 grams per kilogram of body weight across the entire marathon, a fueling rate consistent with general endurance-sport guidance.

The glucose traces themselves told a reassuring story. Median capillary glucose measured by glucometer stood at 183.5 mg/dL at the start, within the planned pre-race target, then fell to 119.5 mg/dL at 10 km, rose to 142.5 mg/dL at 19 km, dipped to 121.5 mg/dL at 30 km and finished at 108.5 mg/dL. These values remained within or close to a safe range throughout, showing that the pre-race insulin reductions and steady carbohydrate intake kept the runners’ blood sugar from collapsing under the metabolic demands of the distance. Only two hypoglycaemic measurements occurred, and both were in the same participant, who nevertheless completed the race. Notably, that runner had started with a glucose level below 140 mg/dL, beneath the study’s recommended pre-race floor, and consumed 49.5 grams of carbohydrate per hour, slightly less than the group median.

But the study also delivered a caution about the very technology that made it possible. CGM accuracy deteriorated substantially during the marathon. The intermittently scanned system differed from glucometer measurements by an average of approximately 43 per cent, and the real-time system by approximately 37 per cent. Both sensors overestimated capillary glucose, by +32.2 mg/dL and +50.4 mg/dL respectively. This matters because a runner who trusts an inflated sensor reading may believe their glucose is safe when it is in fact falling toward hypoglycaemia. Sensor error during prolonged exercise is thought to arise from a combination of factors, including reduced subcutaneous blood flow as the body shunts blood to working muscle, sweat interfering with sensor adhesion, compression of the sensor site, and the lag between interstitial fluid glucose, which CGM devices measure, and blood glucose, which changes fastest during rapid metabolic swings.

The authors drew a practical conclusion from this discrepancy. In a statement, they said: In this small observational study, all runners with type 1 diabetes completed the marathon, with performance comparable to controls. The runner who experienced low blood sugar had started the race with a glucose level below 140 mg/dL. During the marathon, CGM readings differed from glucometer measurements. For longer endurance events, runners should therefore consider checking their glucose with a glucometer, especially when the sensor reading does not match how they feel. That advice effectively reframes CGM as a trend-monitoring tool rather than a standalone decision-making instrument during ultra-endurance efforts, with fingerstick confirmation reserved for moments when symptoms and sensor numbers diverge.

The research team emphasised that the findings should not be read as a green light for unsupervised endurance racing. They noted that fear of hypoglycaemia is the main barrier to physical activity and affects up to 45 per cent of people with type 1 diabetes despite the major health benefits of regular exercise, and that managing glucose is challenging when levels change rapidly and responses vary between individuals. Their message was nonetheless an optimistic one: with appropriate education and careful blood sugar management, people with type 1 diabetes can successfully take part in even very demanding endurance exercise. They advised anyone with type 1 diabetes preparing for a marathon to discuss an individual glucose, carbohydrate and hydration plan with their doctors before the event, stressing that the most important element is an appropriate insulin management strategy, including reductions in basal and prandial insulin, and that baseline glucose control, exercise experience, diabetes duration and complications all shape individual risk. Some people, they added, should consult a cardiologist before starting endurance training. The team, which supports many athletes with type 1 diabetes, including competitors at the Olympic Games, Ironman triathlon finishers and a runner who completed ten marathons in ten consecutive days, presents the study as further evidence that the condition need not disqualify anyone from the marathon start line, provided the science of glucose management is respected as rigorously as the training plan itself.

Subject of Research: Glucose management, carbohydrate intake and CGM accuracy in amateur marathon runners with type 1 diabetes during a real-world 42 km race

Article Title: Running marathons with type 1 diabetes can be safe, shows small study using continuous glucose monitoring devices

Article References: Running marathons with type 1 diabetes can be safe, shows small study using continuous glucose monitoring devices. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: type 1 diabetes, marathon, continuous glucose monitoring, hypoglycaemia, endurance exercise, insulin adjustment, carbohydrate intake, CGM accuracy, MARD, EASD, sports medicine, glucose management